Radiopharmaceutical therapy (RPT) is now widely recognized as an effective modality transforming cancer management. Within the last decade, prospective clinical trials using 177Lu-labeled therapies have led to the widespread adoption of [177Lu]Lu-DOTA-octreotate therapy for patients with
No takes yet. Share an insight, caveat, or question.
Kong et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: